Quantbot Technologies LP acquired a new position in Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,654 shares of the life sciences company’s stock, valued at approximately $528,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Advisory Services Network LLC lifted its stake in shares of Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares during the last quarter. Penserra Capital Management LLC lifted its stake in shares of Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after acquiring an additional 102 shares during the last quarter. Dupont Capital Management Corp bought a new stake in shares of Illumina in the 3rd quarter valued at about $153,000. Paradigm Asset Management Co. LLC lifted its stake in shares of Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after acquiring an additional 50 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. lifted its stake in shares of Illumina by 11.3% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after acquiring an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 90.76% of the company’s stock.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $211.35, for a total transaction of $4,227,000.00. Following the transaction, the director now owns 531,717 shares in the company, valued at approximately $112,378,387.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jay T. Flatley sold 22,540 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total value of $4,400,033.40. Following the transaction, the director now owns 539,176 shares in the company, valued at approximately $105,252,546.96. The disclosure for this sale can be found here. Insiders have sold a total of 192,446 shares of company stock worth $39,713,114 in the last quarter. Company insiders own 0.89% of the company’s stock.

Illumina, Inc. (ILMN) opened at $214.86 on Friday. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $216.08. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $31,369.56, a P/E ratio of 62.82, a price-to-earnings-growth ratio of 3.55 and a beta of 0.74.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. During the same quarter in the prior year, the business earned $0.97 EPS. The business’s revenue for the quarter was up 17.6% on a year-over-year basis. equities research analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.

ILMN has been the subject of a number of recent research reports. Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $209.78 target price for the company in a research note on Wednesday, August 9th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and boosted their target price for the company from $170.00 to $215.00 in a research note on Monday, August 7th. Argus boosted their target price on Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, September 13th. Deutsche Bank AG raised Illumina from a “hold” rating to a “buy” rating and lowered their target price for the company from $195.00 to $160.00 in a research note on Monday, October 23rd. Finally, Bank of America Corporation boosted their target price on Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a research note on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $200.88.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/2654-shares-in-illumina-inc-ilmn-purchased-by-quantbot-technologies-lp/1726920.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.